Details for Patent: 9,066,942

Which drugs does patent 9,066,942 protect, and when does it expire?

Patent 9,066,942 protects TUXARIN ER and is included in one NDA.

Summary for Patent: 9,066,942

Patent landscape, scope, and claims:

Title:	Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
Abstract:	The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is about 4.times.10.sup.-4 moles to about 2.0.times.10.sup.-3 moles.
Inventor(s):	Giliyar; Chandrashekar (Salt Lake City, UT), Nachaegari; Satish Kumar (Salt Lake City, UT), Nachiappan; Chidambaram (Sandy, UT), Patel; Mahesh V. (Salt Lake City, UT), Venkateshwaran; Srinivansan (Salt Lake City, UT)
Assignee:	Spriaso LLC (Salt Lake City, UT)
Application Number:	14/194,523
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 9,066,942

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mainpointe	TUXARIN ER	chlorpheniramine maleate; codeine phosphate	TABLET, EXTENDED RELEASE;ORAL	206323-001	Jun 22, 2015		RX	No	No	9,066,942					TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS